Biotechnology

Eli Lilly and Company is constructing the $4.5 billion Lilly Medicine Foundry in Lebanon, Ind. The 1.2 million-sf center will combine research and advanced manufacturing with the latest technology to innovate new production methods and scale global access to medicines for clinical trials. Featuring a flexible layout, the seven-building complex will create various molecular therapies, including drug substances for small molecules, biologics, and nucleic acid therapeutics. 

Mass timber construction is widely lauded for its sustainability benefits, including wood’s natural carbon sequestration, lower embodied energy footprint, lighter weight compared to steel or concrete, and essential renewability. But does it pay off in terms of a university’s performance standards and cost concerns when embarking on a project as ambitious as Oregon State University’s Jen-Hsun and Lori Mills Huang Collaborative Innovation Complex, a $213 million, 143,000-sf facility dedicated to advanced programs in artificial intelligence, robotics, energy, and materials science? Scott Ashford, OSU’s dean of the College of Engineering, and Libby Ramirez, the university’s resident architect, argue that with careful strategy and an eye toward the data, the answer is “yes.”

FUJIFILM Biotechnologies opened a $3.2 billion pharmaceutical manufacturing facility in September of 2025 in Holly Springs, N.C. Integrating leading-edge equipment and technologies, the sophisticated development features eight 20,000-liter bioreactors for the production of bulk drug substances and innovative therapies. Johnson & Johnson and Regeneron have signed 10-year contracts to secure space at the 1.3 million-sf campus, which represents the largest end-to-end cell culture CDMO hub in North America. 

The University of Pittsburgh is constructing the state-of-the-art BioForge center in the Hazelwood Green development, a brownfield site site that once accommodated a steel mill. Designed by HOK, the $250 million hub will drive breakthroughs and innovations in the manufacturing of precision biological medicines to improve human health.

Southern Research opened a $98 million biotechnology center in August of 2025 in Birmingham, Alabama. Designed by HOK and Williams Blackstock Architects, the 150,000-sf building will advance research crucial to human health and address pressing biomedical threats. The five-level structure features BSL-3 laboratories spanning 7,500 sf that provide essential biocontainment capacity for the study of infectious diseases.

GenesisM, a joint venture between Bain Capital and Botanic Properties, broke ground on a Class A biomanufacturing facility in July of 2025 in Bedford, Mass. Designed by Perkins&Will, the sophisticated development addresses a critical need for purpose-built life sciences infrastructure in the Greater Boston region.

Merck broke ground in April of 2025 on a $1 billion biologics center of excellence in Wilmington, Del. Leveraging sophisticated automation solutions and artificial intelligence technologies, the 470,000-sf facility will offer laboratory, manufacturing, and logistics capabilities. The leading-edge structure will enable the launch and commercial production of next-generation biologics and therapies, including potent antibody-drug conjugates (ADCs).

Roche announced the launch of the Roche Genentech Innovation Center in March of 2025 on Harvard’s Enterprise Research Campus in Allston. With an initial lease of 30,000 sf of lab space in the first phase of construction, Roche intends to expand their R&D presence to eventually accommodate 500 employees. The initiative will bring together cardiovascular, renal, and metabolism experts with data science and AI specialists to accelerate innovation in drug discovery and development.

An evolution of the equipment and technology researchers need is transforming ordinary labs into facilities that deserve to be called next-generation or future-ready. Significant changes in space utilization and lab planning and design are driven by increased automation and robotics, the incorporation of manufacturing, enhanced information technology with an emphasis on data collection, ever-evolving technologies, developer core/shell fit-outs, hybrid work patterns, and different approaches to project delivery and construction. 

MilliporeSigma, a subsidiary of Merck KGaA, opened a $317.2 million facility in Rockville in October of 2024. Located in the Alexandria Center at Traville Gateway, the 260,000-sf building provides advanced laboratories for biosafety testing, analytical development, viral clearance, and cell bank manufacturing. The project represents the company's largest investment to date in contract testing operations.

The Oxford Science Park is expanding in the United Kingdom to provide sophisticated environments for research and discovery. Three new buildings will rise in the innovation district, which is majority owned by Oxford University's Magdalen College. Designed by Scott Brownrigg, The Daubeny Project will offer a total of 450,000 sf of leading-edge life science space supported by enhanced lab infrastructure. Dramatic colonnades on the ground floor will open onto light-filled areas for reception, interaction, and collaboration.

BeiGene opened an $800 million center for biologics manufacturing and research in July of 2024 in Hopewell, N.J. Sited on 42 acres at the Princeton West Innovation Campus, the development provides 400,000 sf of dedicated space for commercial-stage production of cancer therapies. A 100,000-sf lab building accommodates clinical R&D suites and collaborative office settings. As BeiGene's U.S. headquarters and flagship manufacturing facility, the highly flexible complex integrates universal design principles to create an adaptable, human-centric environment.

BXP recently completed a 113,000-rsf innovation hub in Waltham, Mass. Designed by TRIA, 103 CityPoint aims to reshape corporate culture for science and technology tenants, energizing its workforce and accelerating growth. The flexible flour-story structure provides 80 percent laboratory and office space, with 20 percent accommodating a double-height cGMP manufacturing area spanning approximately 25,000 sf.

The Davis Companies and Invesco Real Estate completed construction in June of 2024 on a 215,000-sf research facility in Cambridge. Designed by Jacobs, 101 Smith Place is the third structure in a new life sciences cluster called The Quad and offers 161,616 rsf of Class A lab and office space. Features include:

Merck is expanding its Darmstadt headquarters campus with the construction of a $66 million quality control facility for MilliporeSigma, the company’s life science business. Spanning approximately 105,000 sf, the four-story building will provide GMP labs and cleanrooms for the testing of medicines and biological agents. The flexible structure is designed to enhance operational efficiencies and will bring 135 employees from different departments together in one collaborative location.